Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRAFFT-WHF study of COR-1167 for worsening heart failure
2024-518951-52-00Phase 2Suspended
- Sponsor
- Corteria Pharmaceuticals
- Start
- Nov 2025
- Modality
- Small Molecules, Peptides
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in heart failure (HF) comparing COR-1167 with Placebo (2 arms). Primary endpoints: Dose-effect on natriuresis, Dose-effect on body weight and 3 more. Started Nov 2025; status: suspended.
02
Drugs
COR-1167
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on 2024-518951-52-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518951-52-00.